Safety and efficacy of endoscopic treatment with mucosal resection, radiofrequency ablation, and cryotherapy in the curative treatment of early esophageal squamous cell cancer and dysplasia.
4055 Background: Endoscopic esophageal treatment (EET), by radiofrequency ablation (RFA), cryoablation (Cryo), and endoscopic mucosal resection (EMR) has not been extensively studied in early esophageal squamous cell carcinoma (SCC). Aim: To assess the safety and success of EET in curative treatment of early esophageal SCC: (T1a, T1b, T2) and squamous cell dysplasia (SCD). Methods: We retrospectively reviewed records of patients with SCC (T1a, T1b, T2) and SCD treated with EET from January 2010 to August 2024. All patients had at least one follow-up endoscopic biopsy after treatment. Results: 62 patients met the eligibility criteria. Table. 46 patients (74%) had T1a (n=36.5%) or T1b (n=10.1%) SCC. T2 patients (21%) received ETT for local recurrence after chemoradiation. The most frequent ETT was EMR + RFA, n= 26 (41.9%) and RFA, n=20 (32%). In the first biopsy after treatment, 46 of the 62 patients (74.1%) had no residual cancer. This number increased after further ETT. 2 years after treatment only 4 patients had persistent cancer. BMI is significantly associated with survival status. No patient had disease progression that required surgery. Strictures formed in 15 patients (24%) post- ETT. Conclusions: ETT provides curative treatment of early SSC in up to 94% of patients. Association between cancer persistence at first post-biopsy with various demographic and clinical variables. Patient Characteristics Total N=62 P-value Sex (%) Male 28 (45.16%) 0.49 Female 34 (54.84%) Race (%) White / Caucasian 52 (83.87%) 0.716 Hispanic 2 (3.23%) Black 2 (3.23%) Asian 4 (6.45%) BMI, median (range) N = 62 24.02 (15, 44.5) 0.045 Smoking Status (%) No 25 (40.32%) 0.182 Yes 37 (59.68%) Alcohol Drinking (%) No 22 (35.48%) >0.99 Yes 40 (64.52%) Squamous Dysplasia (%) none 59 (95.16%) >0.99 Low 1 (1.61%) High 2 (3.23%) Squamous tumor staging (%) none 3 (4.84%) 0.174 T1a 36 (58.06%) <jats:td colspan
Authors
- Mehnaz A. Shafi (ORCID: https://orcid.org/0000-0003-2614-7580)
- Sidra Naz (ORCID: https://orcid.org/0000-0001-6390-9658)
- Ahmed Elhariri (ORCID: https://orcid.org/0000-0002-3715-4842)
- Matthew Manuel (ORCID: https://orcid.org/0000-0002-7560-076X)
- Wei Qiao (ORCID: https://orcid.org/0000-0002-0922-0726)
- Marta Davila
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1200/jco.2025.43.16_suppl.4055
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00